Key terms
About APVO
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest APVO news
Apr 11
8:41am ET
Aptevo Therapeutics prices 3.4M shares at $1.35 in public offering
Mar 08
10:46am ET
Biotech Alert: Searches spiking for these stocks today
Mar 07
9:40am ET
Aptevo Therapeutics trading resumes
Mar 07
9:35am ET
Aptevo Therapeutics trading halted, volatility trading pause
Mar 07
9:00am ET
Aptevo, Alligator Bioscience report interim data of ALG.APV-527 Phase 1 trial
Mar 07
7:28am ET
Aptevo price target adjusted to $10.50 from $4.75 at Alliance Global Partners
Mar 05
7:50pm ET
Aptevo Therapeutics trading halted, news pending
Mar 04
9:07am ET
Aptevo Therapeutics announces 1-for-44 reverse stock split
Feb 07
5:04am ET
Aptevo Therapeutics Stockholders Approve Reverse Split
No recent press releases are available for APVO
APVO Financials
Key terms
Ad Feedback
APVO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
APVO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
